整合机器学习与分子对接解析附子治疗心力衰竭的分子网络OA
Integrating Machine Learning and Molecular Docking to Decipher the Molecular Network of Fuzi in Treating Heart Failure
附子被誉为"回阳救逆第一要药",在心力衰竭的临床治疗中疗效确切,然而其分子调控网络及具体机制尚未得到系统而深入的阐明.本研究整合基因表达(Gene Expression Omnibus,GEO)数据库筛选与心力衰竭相关的差异表达基因,并利用公共数据库挖掘附子活性成分及其作用靶点;进一步运用机器学习算法与分子对接技术遴选核心基因,追踪其下游信号蛋白,系统解析附子活性成分与靶蛋白的结合特性.结果显示,附子抗心力衰竭的潜在作用靶点共鉴定出23个.基于机器学习筛选出C-C趋化因子受体1(C-C Motif Chemokine Receptor 1,CCR1)、环氧化物水解酶2(Epoxide Hydrolase 2,EPHX2)、膜金属内肽酶(Membrane Metalloendopeptidase,MME)、胞外-5-核苷酸酶('5'-Nucleotidase Ecto,NT5E)、磷酸二酯酶5A(Phosphodiesterase 5A,PDE5A)、磷脂酶A2 IIA组(Phospho-lipase A2 Group IIA,PLA2G2A)等6个关键特征基因.分子对接分析证实,附子中苯甲酰乌头原碱、飞燕草素3,5-双葡萄糖苷、惰碱和伊夫双苷等4种活性成分与EPHX2、MME及PDE5A等3个核心基因具有强结合特异性.进一步在阿霉素(Doxorubicin,DOX)诱导心力衰竭小鼠模型中,发现附子能够通过抑制EPHX2、MME及PDE5A表达,改善DOX引起的心肌萎缩并逆转心肌损伤.蛋白互作数据库预测显示PDE5A与Rho相关BTB结构域蛋白1(RHOBTB1 Rho related BTB domain containing 1,RHOBTB1)相互作用,其结合能为-66.1 kJ/mol,提示RHOBTB1可能为PDE5A的下游结合蛋白.综上所述,附子可能通过调控PDE5A/RHOBTB1信号轴发挥抗心力衰竭作用,为深入解析其分子机制提供了新的视角与理论依据.
Fuzi is known as the first key medicine to restore depleted Yang and rescue the patient from danger in Traditional Chinese Medicine(TCM)theory and its clinical efficacy in treating heart failure has been definitely demonstrated.However,its molecular regulatory network and specific mechanisms have not yet been systematically and thoroughly elucidated.This study integrated the Gene Expression Omnibus(GEO)database to screen differentially expressed genes related to heart failure and combined public data-bases to identify active components of Fuzi and their target genes.Furthermore,machine learning algorithms and molecular docking technology were applied to select core genes and trace their downstream signaling proteins,systematically analyzing the binding characteristics between active components of Fuzi and target proteins.The results revealed 23 potential targets involved in the anti-heart failure effects of Fuzi.Six key feature genes—C-C Motif Chemokine Receptor 1(CCR1),Epoxide Hydrolase 2(EPHX2),Membrane Metalloendopeptidase(MME),'5'-Nucleotidase Ecto(NT5E),Phosphodiesterase 5A(PDE5A),and Phospholipase A2 Group IIA(PLA2G2A)—were screened using machine learning algorithms.Molecular docking confirmed strong binding specificity between four active components of Fuzi—delphinidin 3,5-diglucoside,bebzoylaconine,ignavine,and evobioside—with three core proteins:EPHX2,MME,and PDE5A.Furthermore,in a doxorubicin(DOX)-induced heart failure model,we discovered that Fuzi rescued DOX-induced myocardial atrophy and reversed cardiac injury by suppressing the expression of EPHX2,MME,and PDE5A.Protein-protein interaction database prediction indicated a direct interaction between PDE5A and RHOBTB1 Rho related BTB do-main containing 1(RHOBTB1)with a binding energy of-66.1 kJ/mol,,suggesting RHOBTB1 as a downstream binding protein of PDE5A.In summary,Fuzi may exert its anti-heart failure effects by regulating the PDE5A/RHOBTB1 signaling axis,providing new insights and a theoretical basis for further elucidating its molecular mechanisms.
陈贻丹;姚静静;李震宇;秦雪梅
山西中医药大学 太行本草研究院,山西 晋中 030619山西中医药大学 太行本草研究院,山西 晋中 030619山西中医药大学 太行本草研究院,山西 晋中 030619||山西大学 中医药现代研究中心,山西 太原 030006山西中医药大学 太行本草研究院,山西 晋中 030619||山西大学 中医药现代研究中心,山西 太原 030006
医药卫生
附子心力衰竭磷酸二酯酶5A
Fuziheart failurePhosphodiesterase 5A
《山西大学学报(自然科学版)》 2026 (3)
400-415,16
国家自然科学基金(82505236)山西省基础研究计划青年项目(202403021212245)山西省中医药管理局科研课题(2024ZYY2B059)山西省高等学校科技创新项目(2024L266)中药生命组学与创新药物研发研究室(zyyyjs2024019)山西中医药大学博士科研启动基金(2024BK01)山西中医药大学优秀博士毕业生来晋工作奖励经费科研启动基金(2024BKS04)山西中医药大学科技创新能力培育计划基础与临床合作研究专项(2024PY-JL-20-02)山西中医药大学科技创新能力培育计划国家自然科学基金培育专项(2024PY-NS-025)山西中医药大学研究生科研实践创新项目(X2025KY020)
评论